STOCK TITAN
  1. Home
  2. Sec-filings
  3. BBNX
  4. [Form 4] Beta Bionics, Inc. Insider Trading Activity

Beta Bionics director reports Form 4 sales under Rule 10b5-1

Filing Impact
(Neutral)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Beta Bionics (BBNX) director reported open-market sales on 10/31/2025 under a Rule 10b5-1 plan adopted July 31, 2025. Two transactions were disclosed: 1,287 shares at a weighted average price of $26.8588 (range $26.27–$27.22) and 119 shares at a weighted average price of $27.4502 (range $27.32–$27.57).

Following these trades, the reporting person directly beneficially owns 9,841 shares. The filing notes full trade breakdowns by price increment are available upon request.

Positive

  • None.

Negative

  • None.
Insider Palasis Maria
Role Director
Sold 1,406 shs ($38K)
Type Security Shares Price Value
Sale Common Stock 1,287 $26.8588 $35K
Sale Common Stock 119 $27.4502 $3K
Holdings After Transaction: Common Stock — 9,960 shares (Direct)
Footnotes (1)
  1. Represents shares sold pursuant to a Rule 10b5-1 Plan adopted on July 31, 2025. The weighted average sale price for the transaction reported was $26.8588 and the range of prices were between $26.27 and $27.22. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. The weighted average sale price for the transaction reported was $27.4502 and the range of prices were between $27.32 and $27.57. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
 Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Palasis Maria
(Last) (First) (Middle)
C/O BETA BIONICS, INC.
11 HUGHES
(Street)
IRVINE CA 92618
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Beta Bionics, Inc. [ BBNX ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
10/31/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 10/31/2025 S(1) 1,287 D $26.8588(2) 9,960 D
Common Stock 10/31/2025 S(1) 119 D $27.4502(3) 9,841 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Represents shares sold pursuant to a Rule 10b5-1 Plan adopted on July 31, 2025.
2. The weighted average sale price for the transaction reported was $26.8588 and the range of prices were between $26.27 and $27.22. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
3. The weighted average sale price for the transaction reported was $27.4502 and the range of prices were between $27.32 and $27.57. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
/s/ Stephen Feider, Attorney-in-Fact 11/05/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What did BBNX disclose in this Form 4?

A director reported two open-market sales on 10/31/2025 under a Rule 10b5-1 plan.

How many BBNX shares were sold and at what prices?

Two sales: 1,287 shares at a weighted average $26.8588 (range $26.27–$27.22) and 119 shares at $27.4502 (range $27.32–$27.57).

When was the Rule 10b5-1 plan adopted for BBNX?

The plan was adopted on July 31, 2025, and the reported sales were made pursuant to it.

How many BBNX shares does the reporting person now own?

Following the transactions, the reporting person directly beneficially owns 9,841 shares.

What is the insider’s relationship to Beta Bionics (BBNX)?

The reporting person is a Director of Beta Bionics, Inc.

Can I see the detailed price breakdowns for these sales?

Yes. The filing states complete trade details by price increment will be provided upon request to the SEC staff, the Issuer, or any security holder.